Browse by category

A study by researchers from the University of California San Diego has revealed compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists may do more than regulate blood sugar and weight. In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking GLP-1 medications were less than half as likely to die within five years, compared to those who weren't on the drugs (15.5% versus 37